Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 12/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473636 | 0.93 | MAPT (0.51) | ALKHTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL5460786 | 0.86 | MAPT (0.48) | ALKHTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL5459753 | 0.84 | MAPT (0.45) | ALKHTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL5467463 | 0.84 | GFER (0.51) | MAPTNPC1RAB9ALCKPDGFRB | |
| SCHEMBL5460880 | 0.83 | MAPT (0.49) | MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5465476 | 0.82 | MAPT (0.49) | HTR1AHTR1DHTR1BHTR2AMAPT | |
| SCHEMBL5484266 | 0.82 | MAPT (0.58) | HTR1AHTR1DHTR1BHTR2AMAPT | |
| SCHEMBL5460915 | 0.82 | MAPT (0.48) | MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5459135 | 0.81 | GLA (0.48) | MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5460053 | 0.81 | GLA (0.48) | ALKMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | ALK 3756/4885HTR1A 2801/4885HTR1D 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.